RHUMBLINE ADVISERS

Position in CLLS — Cellectis S.A.

CIK 1115418 BOSTON, MA

Position in CLLS

as of Jun 30, 2026 · filed Aug 12, 2026 Compact

Position Value

$42,984

-$4,835 QoQ

Shares Held

14,328

-5.0% QoQ

Ownership

0.014%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#12

of 27 holders

Holding Since

Jun 2023

13 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

RHUMBLINE ADVISERS holds $1,414,750,230 across 329 Biotechnology names. CLLS ranks #295 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	396,380	$196,893,837
2	REGN	Regeneron Pharmaceuticals, Inc.	157,794	$98,390,870
3	MRNA	Moderna, Inc.	809,853	$56,714,005
4	ALNY	Alnylam Pharmaceuticals, Inc.	165,579	$49,844,246
5	INCY	Incyte Corp	428,533	$48,578,500
6	RVMD	Revolution Medicines, Inc.	226,008	$42,326,778
7	ROIV	Roivant Sciences Ltd.	1,178,789	$41,717,342
8	JAZZ	Jazz Pharmaceuticals plc	163,018	$39,282,447

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$42,984	14,328	-5.0%	Shares	Sole	2026-08-12
2026-03-31	$47,819	15,085	+13.1%	Shares	Sole	2026-05-12
2025-12-31	$64,580	13,343	+817.0%	Shares	Sole	2026-02-13
2025-09-30	$4,146	1,455	-23.6%	Shares	Sole	2025-11-06
2025-06-30	$2,905	1,905	-9.9%	Shares	Sole	2025-08-12
2025-03-31	$2,622	2,115	0.0%	Shares	Sole	2025-05-29
2024-12-31	$3,807	2,115	-45.1%	Shares	Sole	2025-05-29
2024-09-30	$8,172	3,855	0.0%	Shares	Sole	2024-11-12
2024-06-30	$7,208	3,855	0.0%	Shares	Sole	2024-08-01
2024-03-31	$10,215	3,855	0.0%	Shares	Sole	2024-05-09
2023-12-31	$11,873	3,855	+29.8%	Shares	Sole	2024-02-08
2023-09-30	$4,692	2,970	0.0%	Shares	Sole	2023-11-09
2023-06-30	$5,844	2,970	—	Shares	Sole	2023-08-08
No filing history on record for this holder in this stock.